Sequence 3 from Patent US 20070264275

General Information


DRACP ID  DRACP01295

Peptide Name   Sequence 3 from Patent US 20070264275

Sequence  LPPDVQRV

Sequence Length  8

UniProt ID  P50757  P08253 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01295

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C41H70N12O12

Absent amino acids  ACEFGHIKMNSTWY

Common amino acids  PV

Mass  104812

Pl  6.34

Basic residues  1

Acidic residues  1

Hydrophobic residues  3

Net charge  0

Boman Index  -1618

Hydrophobicity  -31.25

Aliphatic Index  121.25

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2007/0264275 A1

Patent Title  Peptides Derived from the Protein Mmp-4, and the Use Thereof in Antitumoral Immunotherapy.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status: Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009

Other Published ID  CA2529943A1  EP1635862A1  US7629439  WO2005000342A1 




DRACP is developed by Dr.Zheng's team.